Clene Inc CLNN

$4.08 +0.06 (1.49%)

Valuation

Market cap
53,016,000
Revenue TTM
$200,000
Net income TTM
$-26,170,000
PE ratio
0.00
Forward PE
—
Profit margin
-13,085.00%
Debt to equity
-0.22

Trading

Volume
61,400
Avg volume
106,276
Day's range
$3.97 – $4.17
Shares out
12,994,000
Stochastic %K
15%
Beta
0.91
Analysts
Strong Sell
Price target
$32.00

Price

Company profile

Clene Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of novel clean-surfaced nanotechnology (CSN) therapeutics. The company's lead drug candidate is CNM-Au8, which is being studied in various clinical trials, including a completed Phase 2 platform trial to evaluate the safety and efficacy of CNM-Au8 in patients with amyotrophic lateral sclerosis (ALS); comp...

Show more

Clene Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of novel clean-surfaced nanotechnology (CSN) therapeutics. The company's lead drug candidate is CNM-Au8, which is being studied in various clinical trials, including a completed Phase 2 platform trial to evaluate the safety and efficacy of CNM-Au8 in patients with amyotrophic lateral sclerosis (ALS); completed Phase 2 proof of concept clinical trial in patients with early symptomatic ALS; completed two open-label investigator blinded Phase 2 clinical trials on the brain's energy metabolites; completed Phase 2 clinical trial for the treatment of visual pathway deficits in chronic optic neuropathy for remyelination in stable relapsing Multiple Sclerosis; and a second Phase 2 clinical trial for the treatment of patients with Parkinson's Diseases. It develops CNM-AgZn17, a gel polymer suspension of silver and zinc ions that is being developed for the treatment of infectious diseases and to support wound healing; and CNM-ZnAg, a broad-spectrum antiviral and antibacterial agent to treat infection disease and to provide immune support for symptom resolution. In addition, the company markets and distributes dietary supplements comprising rMetx, an aqueous zinc-silver ion dietary supplement; and KHC46, an aqueous gold dietary supplement of very low-concentration Au nanoparticles. Clene Inc. is headquartered in Salt Lake City, Utah.

Industry
Packaged Foods
Sector
Consumer Defensive
Phone
801 676 9695
Website
https://clene.com
Address
6550 South Millrock Drive, Suite G50, Salt Lake City, United States

Latest news

Stocktwits

Bbbb44444 Oct 2, 6:39 PM
$CLNN I had no idea about Chris Johnson’s ALS diagnosis until recently. https://www.google.com/url?sa=t&source=web&rct=j&opi=89978449&url=CAESYwHrOzAVay-aIswP-V1j_FyyP31wqjs0sRzp2g17fBaw75QYS8D3ocwnYA0pyf6uwkqySd8dYDX9dGlEuS3G1OLzdoaeZXf-8iaJfguWXhwkMtOSHlXJngzY4pSYJqDYSIO1CQ&ved=2ahUKEwjOv9Ks_ZuXAxU9TDABHYizPZUQtwJ6BAgnEAI&uoh=2&usg=AOvVaw0x6hrzJWkfzQLlF6K94nQm
0 replies
neuroinvestor3 Oct 2, 6:10 PM
$CLNN Latest ChatGPT odds - I'd break the regulatory path into roughly four hurdles: Hurdle My assessment FDA accepts NDA for review ~75–90% FDA agrees accelerated-approval pathway is appropriate ~55–70% FDA concludes NfL evidence + clinical evidence supports benefit-risk ~50–60% Actual accelerated approval ~40–55% What could push the odds toward 60–70% The biggest positive catalyst would be an FDA response to the NDA indicating that: the NfL effect is sufficiently large and reproducible; the NfL-to-clinical-benefit relationship is persuasive; the responder analysis adequately addresses the post-hoc nature of the data; the safety profile remains favorable; and FDA is comfortable relying on RESTORE-ALS as the confirmatory trial. CNM-Au8's safety profile is actually a relative strength. The planned Phase 3 trial is also designed specifically to prospectively evaluate the NfL relationship, which addresses one of the biggest weaknesses.
0 replies
Mulhollandr Oct 2, 4:26 PM
$CLNN $BCLI $NRSN $COYA If you didn’t follow her, you were missing out. Brooke handled her ALS journey with amazing grace and humor. RIP Brooke Eby
2 replies
Chris150 Oct 2, 4:13 PM
$CLNN Just FYI about NDA: The eCTD (Electronic Common Technical Document) is the mandatory digital format used by the U.S. Food and Drug Administration (FDA) for submitting an NDA (New Drug Application), along with BLAs, ANDAs, commercial INDs, and master files. • Key Requirements & Structure: Mandatory Format: Paper or PDF-only submissions are no longer accepted for original NDAs. All filings must go through the FDA Electronic Submissions Gateway (ESG). • Five-Module Structure: The dossier is organized into five standard parts: • Module 1: Region-specific administrative information and prescribing data (e.g., FDA Form 356h, cover letters). • Module 2: Common Technical Document summaries (Quality Overall Summary, Nonclinical Overview/Summary, Clinical Overview/Summary). • Module 3: Quality (Chemistry, Manufacturing, and Controls - CMC). • Module 4: Nonclinical study reports (pharmacology, pharmacokinetics, toxicology). • Module 5: Clinical study reports and efficacy/safety data.
0 replies
Mulhollandr Oct 2, 3:45 PM
$CLNN
0 replies
Fidia Oct 2, 1:51 PM
$CLNN ​"I set up an auto-buy for 20 shares every day for a few months and managed to accumulate 3,000 shares. I truly believe CLNN is going to make a huge run by the end of this year. Especially with short sellers being forced to cover, which I think will really drive the price up lol.
0 replies
Jumpmanz Oct 2, 2:25 AM
$CLNN
1 replies
Ravery Oct 2, 1:31 AM
$CLNN fyi Cannacord: We still include CNM-Au8 for ALS and multiple sclerosis (MS) at probabilities of approval of 45% and 20%, respectively Jones: In our base case, we assign a 40% probability of success (POS) to CNM-Au8 in ALS. In our bull case, we assume that encouraging feedback emerges from interactions with the FDA. We increase the POS to 50%. This results in a fair value/price target of $42 per share. In our bear case, we assume negative or mixed regulatory feedback and reduce our POS for CNM-Au8 to 15%. This results in a fair value/price target of $1 per share.
1 replies